Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration.
Martin StattinJulia ForsterDaniel AhmedAnna-Maria HaasAlexandra GrafKatharina KreplerSiamak Ansari-ShahrezaeiPublished in: Journal of ophthalmology (2020)
Our data confirm an absolute vision loss in eyes compromised by nAMD after 7 years of continuous VEGF inhibition. The visual decline was significantly related to baseline VA as well as the number of injections. We suggest following patients thoroughly independent of the initial VA and a greater incentive for the physician to treat.
Keyphrases
- vascular endothelial growth factor
- age related macular degeneration
- endothelial cells
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- emergency department
- primary care
- optical coherence tomography
- peritoneal dialysis
- prognostic factors
- type diabetes
- big data
- electronic health record
- ultrasound guided
- deep learning
- skeletal muscle
- patient reported